Background: As honeybees are the main pollinator species subject to an intense research regarding effects of pesticides, other ecologically important native bee pollinators have received little attention in ecotoxicology and risk assessment of pesticides in general, and insecticides in particular, some of which are perceived as reduced-risk compounds. Here the impact of three reduced-risk insecticides -azadirachtin, spinosad, and chlorantraniliprole -was assessed in two species of stingless bees, Partamona helleri and Scaptotrigona xanthotrica, which are important native pollinators in Neotropical America. The neonicotinoid imidacloprid was used as a positive control.Results: Spinosad exhibited high oral and contact toxicities in adult workers of both species at the recommended label rates, with median survival times (LT 50 s) ranging from 1 to 4 h, whereas these estimates were below 15 min for imidacloprid. Azadirachtin and chlorantraniliprole exhibited low toxicity at the recommended label rates, with negligible mortality that did not allow LT 50 estimation. Sublethal behavioral assessments of these two insecticides indicated that neither one of them affected the overall group activity of workers of the two species. However, both azadirachtin and chlorantraniliprole impaired individual flight take-off of P. helleri and S. xanthotrica worker bees, which may compromise foraging activity, potentially leading to reduced colony survival.Conclusion: These findings challenge the common perception of non-target safety of reduced-risk insecticides and bioinsecticides, particularly regarding native pollinator species.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.